UNSPSC 51413101: Cilostamide

This classification denotes a phosphodiesterase inhibitor with the molecular formula C20H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45S5605Q18, chemically known as n-cyclohexyl-n-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide but generally known as cilostamide, which bears US NIH Compound Identifier 2753. European Medicines Agency schedules Cilostamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06272MIG.

UNSPSC 51413101 Cilostamide, a Commodity code, nominally names a specific vasodilator medication but covers state and local procurement of advanced life support and emergency-response medications more broadly. State and local governments procure under this code primarily through city emergency services departments and state health authorities buying sealed-bid quantities of injectable cardiac and respiratory medications for fire rescue operations, hospital emergency departments, and pharmacy benefit programs. The scope extends to generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing arrangements and direct-to-manufacturer contracting initiatives. Issuing bodies include municipal purchasing departments (notably the City of Tampa), state health and human services commissions, and multi-state cooperative purchasing alliances such as MMCAP. These buyers typically require vendors to maintain expiration-date minimums, comply with cGMP and Drug Supply Chain Security Act standards, submit Safety Data Sheets, and arrange for expired-product pickup and replacement. Contracts commonly run one to two years with optional renewal periods.

Activity is concentrated in Florida and the upper Midwest, with the City of Tampa and the Texas Health and Human Services Commission posting recent opportunities. The City of Tampa issued IFB 26P00188 on April 24, 2026, seeking 370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem for Tampa Fire Rescue, with sealed bids due April 8, 2026 and an estimated contract value of $40,000.00; the award includes a 5 percent bid discount for Small Local Business Enterprise participation. Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contracts effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement.